Integer Holdings Co. (NYSE:ITGR – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight research firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $149.00.
ITGR has been the subject of a number of recent analyst reports. Citigroup raised their price objective on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Benchmark lifted their price target on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. KeyCorp lifted their price target on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $160.00 price target on shares of Integer in a research report on Tuesday, December 3rd. Finally, Truist Financial lifted their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th.
Check Out Our Latest Stock Report on ITGR
Hedge Funds Weigh In On Integer
Integer Stock Down 0.4 %
Integer stock opened at $118.87 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The stock has a market capitalization of $4.00 billion, a price-to-earnings ratio of 35.38, a PEG ratio of 1.72 and a beta of 1.24. Integer has a 1-year low of $107.11 and a 1-year high of $146.36. The business has a fifty day moving average price of $133.56 and a 200-day moving average price of $132.61.
Integer (NYSE:ITGR – Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The business had revenue of $449.50 million during the quarter, compared to analyst estimates of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. Equities research analysts forecast that Integer will post 6.01 EPS for the current fiscal year.
About Integer
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
See Also
- Five stocks we like better than Integer
- What Investors Need to Know to Beat the Market
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- 3 Warren Buffett Stocks to Buy Now
- 3 Must-Own Stocks to Build Wealth This Decade
- Investing In Preferred Stock vs. Common Stock
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.